FAKHRAVAC () is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III. It received emergency use authorization in Iran on 9 September 2021.
The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh. According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran. Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.The Assassination of Fakhrizadeh: Considerations and Consequences
Medical uses It requires two doses given by intramuscular injection 3 weeks apart.
Pharmacology FAKHRAVAC is an inactivated virus-based vaccine.
Manufacturing In August 2021, production capacity of the vaccine was reported to be 1 million dose per month and was planned to be "multiplied in a few months ". In October 2021, the production was reported to be stopped amid Iran's growing vaccine imports. In January 2022, the Director General of Health of the Ministry of Defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the Iranian Ministry of Health.
Clinical trials +Clinical trials of FAKHRAVACPhaseRegistration numberStartNumber of participantsAge of participantsTotalVaccineControlIIRCT20210206050259N1 8 March 202113596?39? (placebo)18–55 yearsIIIRCT20210206050259N2 8 June 2021500250250 (placebo)18–70 yearsIIIIRCT20210206050259N3 29 August 202141,12820,56420,564 (Sinopharm BIBP vaccine)>18 years
Authorizations
FAKHRAVAC received emergency use authorization in Iran on 9 September 2021. In October 2021, Iran's Food and Drug Administration was considering giving full authorization to the vaccine for third/booster dose.
See also Pharmaceuticals in Iran COVID-19 pandemic in Iran COVID-19 vaccine clinical research
References